Alloga France Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Alloga France Pharmaceutical Import Records from India — 8 Products, $4.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alloga France — Pharmaceutical Importer Profile (2026) | 8 Products, $4.3M Trade | TransData Nexus

Alloga France

Pharmaceutical Importer · Netherlands · Oncology Focus · $4.3M Total Trade · DGFT Verified

Alloga France is a pharmaceutical importer based in Netherlands with a total trade value of $4.3M across 8 products in 3 therapeutic categories. Based on 158 verified import shipments from Indian Customs (DGFT) records, Alloga France is the #1 buyer in 1 product including Cytarabine. Alloga France sources from 6 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 80.7% of imports.

Alloga France — Import Portfolio & Supplier Network

Alloga France import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Alloga France?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$6.9M	732	80.7%
Unichem Laboratories Limited	$641.7K	36	7.5%
Reliance Life Sciences Private Limited

What Formulations Does Alloga France Import?

Formulation	Value	Ships
Pharma drugs & medi irinotecan INJ	$672.5K	22
Pharma drugs & medi ondansetro bls	$225.5K	21
Pharma drugs & medi tadalafil 20MG 3x4taccord-pp-france as per	$188.6K	5
Pharma drugs & medi tadalafil 5MG 2x14taccord-fr as per	$154.6K	5
Pharma drugs medi irinotecan INJ 20MG ML 25ML accor france as per	$150.9K	4
Pharma drugs & medi cabazitaxel 20MG/ML	$147.0K	3
Pharma drugs & medi tadalafil 20MG	$143.0K	6
Pharma drugs & medi argatroban,1MG/ML,50ML(accord-france as per	$129.7K	6
Pharma drugs & medi tadalafil 20MG 3x4t(accord-pp-france as per	$115.7K	8
Amlodipine zentivabes 10MG ka 9x10 vk framlodipine besilate 10MG capsules 9 x 10c21429	$115.5K	3
Pharma drugs medi tadalafil 20MG 2x4t accord pp france as per	$112.0K	6
Pharma drugs & medi irinotecan INJ,20MG/ML,25ML(accor-france as per	$102.1K	4
Lenalidomide 10 MG capsules (21's)	$100.0K	2
Amlodipine zentiva bes 5MG ka 9x10 vk	$98.8K	6
Pravastatine zentiva 20 MG tablets (6x14's)	$97.4K	4

Alloga France imports 357 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Irinotecan	Oncology	$2.4M	50	5.9%	3
2	Cytarabine	Advanced Oncology	$530.3K	36	4.9%	1
3	Cabazitaxel	Advanced Oncology	$386.4K	8	4.2%	4
4	Pravastatin	Cardiovascular	$271.5K	15	0.9%	18
5	Etoposide	Oncology	$235.4K	23	2.2%	9
6	Topotecan	Advanced Oncology	$220.8K	15	5.9%	5
7	Fludarabine	Advanced Oncology	$157.2K	6	5.4%	5
8	Mitoxantrone	Advanced Oncology	$94.2K	5	5.0%	3

Alloga France imports 8 pharmaceutical products across 3 categories into Netherlands totaling $4.3M. The company is the #1 buyer for 1 product: Cytarabine.

Alloga France — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Alloga France is a prominent pharmaceutical logistics company specializing in the distribution and supply chain management of pharmaceutical products. Established in 1958, the company is headquartered in Marseille, France, and operates as a subsidiary within the Alloga network, which offers pan-European pharmaceutical logistics services. Alloga France's primary role involves managing logistics operations for pharmaceutical companies, preparing orders received from pharmacists, hospitals, and wholesalers, and providing services such as serialization, supply chain management, order processing, secondary packaging, and kitting. (craft.co)

In the Netherlands, Alloga France operates through its subsidiary, Alloga Netherlands B.V., located in Veghel. This subsidiary plays a significant role in the Dutch pharmaceutical distribution network, offering a range of services tailored to the specific requirements of the Dutch market. Alloga Netherlands B.V. is part of the broader Alloga network, which provides comprehensive pharmaceutical logistics solutions across Europe.

2Distribution Network

Alloga France's distribution network is extensive, encompassing multiple warehouses and logistics facilities across Europe. In the Netherlands, Alloga operates through its subsidiary, Alloga Netherlands B.V., located in Veghel. This facility is strategically positioned to serve the Dutch market, ensuring efficient distribution and supply chain management. The company's logistics capabilities include advanced warehousing, order processing, and transportation services, enabling it to meet the diverse needs of its clients in the pharmaceutical sector. Alloga's pan-European network allows for seamless distribution across various countries, providing comprehensive coverage and flexibility in logistics operations.

3Industry Role

Alloga France serves as a key logistics intermediary in the pharmaceutical supply chain, facilitating the distribution of pharmaceutical products from manufacturers to end-users, including pharmacies, hospitals, and wholesalers. The company's services encompass a wide range of logistics operations, such as warehousing, order processing, secondary packaging, and kitting, which are essential for ensuring the timely and efficient delivery of pharmaceutical products. By managing these critical aspects of the supply chain, Alloga France plays a pivotal role in maintaining the integrity and reliability of pharmaceutical distribution within the Netherlands and across Europe.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Alloga France

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Alloga France's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a limited number of suppliers. Notably, Intas Pharmaceuticals Limited accounts for 80.7% of the total import value, followed by Unichem Laboratories Limited at 7.5%, and Reliance Life Sciences Private Limited at 4.6%. This concentrated sourcing approach suggests a strategic choice to establish strong, long-term relationships with key suppliers, potentially leading to favorable terms and consistent product quality.

However, such dependency on a few suppliers also introduces risks related to supply chain disruptions, price fluctuations, and potential challenges in negotiating terms. The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent number of shipments over the years. Nonetheless, Alloga France may consider diversifying its supplier base to mitigate potential risks associated with over-reliance on a limited number of sources.

2Supply Chain Resilience

Alloga France's supply chain resilience is influenced by its sourcing strategy and the diversity of its product formulations. The company imports a total of 357 unique pharmaceutical formulations, indicating a broad product portfolio. This diversity can enhance resilience by reducing dependency on specific products and suppliers. However, the high concentration of imports from a few suppliers, particularly from India, may expose the supply chain to risks such as geopolitical tensions, regulatory changes, and logistical disruptions.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the primary regulatory authority overseeing pharmaceutical imports is the Dutch Medicines Evaluation Board (CBG-MEB), which operates under the Ministry of Health, Welfare, and Sport (VWS). The CBG-MEB is responsible for evaluating and monitoring the safety, efficacy, and quality of medicines available in the Dutch market. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. Additionally, the European Union's regulations, such as Regulation (EC) No 726/2004, provide a unified framework for the authorization and supervision of medicinal products across member states.

The marketing authorization pathway for Indian generics involves obtaining approval from the CBG-MEB, which includes submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy. This process ensures that imported generics meet the stringent standards required for distribution in the Netherlands. Collaboration with the CBG-MEB and adherence to EU regulations are essential for Indian exporters aiming to supply pharmaceutical products to the Dutch market.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that companies involved in the importation of medicinal products must obtain the necessary permits from the CBG-MEB. This includes a manufacturer's permit for preparing or importing medicines from outside the European Economic Area (EEA) and a wholesale permit for distributing medicines within the Netherlands. Compliance with the European guidelines on Good Distribution Practice (GDP) is mandatory to ensure the quality and integrity of medicinal products throughout the supply chain. (business.gov.nl)

Alloga France — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Alloga France's product category focus on oncology, advanced oncology, and cardiovascular therapeutics aligns with the growing demand for specialized treatments in these areas. The substantial import values of products like Cytarabine, Irinotecan, and Cabazitaxel indicate a strategic emphasis on high-demand oncology medications. This focus is driven by the increasing prevalence of cancer and cardiovascular diseases, necessitating a reliable supply of effective treatments. By concentrating on these therapeutic areas, Alloga France positions itself to meet critical healthcare needs and strengthen its market presence.

2Sourcing Profile

Alloga France's sourcing strategy for generic drugs involves importing a diverse range of formulations from India, with a significant concentration on oncology and cardiovascular products. The company's preference for sourcing from India is likely due to the country's robust pharmaceutical manufacturing capabilities, cost-effectiveness, and adherence to international quality standards. India's compliance with EU GMP guidelines further enhances its suitability as a sourcing partner for Alloga France.

3Market Positioning

Frequently Asked Questions — Alloga France

What products does Alloga France import from India?

Alloga France imports 8 pharmaceutical products across 3 categories. Top imports: Irinotecan ($2.4M), Cytarabine ($530.3K), Cabazitaxel ($386.4K), Pravastatin ($271.5K), Etoposide ($235.4K).

Who supplies pharmaceuticals to Alloga France from India?

Alloga France sources from 6 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (80.7% of imports, $6.9M).

What is Alloga France's total pharmaceutical import value?

Alloga France's total pharmaceutical import value from India is $4.3M, based on 158 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Alloga France focus on?

Alloga France imports across 3 categories. The largest: Oncology (61.7%), Advanced Oncology (32.0%), Cardiovascular (6.3%).

Get Full Alloga France Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.